<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782106</url>
  </required_header>
  <id_info>
    <org_study_id>160602</org_study_id>
    <nct_id>NCT00782106</nct_id>
  </id_info>
  <brief_title>Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously</brief_title>
  <official_title>Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the feasibility of infusing a full 4-week dose of
      Immune Globulin Intravenous (Human), 10% in a single subcutaneous site and the amount of
      recombinant human hyaluronidase needed to infuse that dose with no more than mild local
      adverse drug reactions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 4, 2006</start_date>
  <completion_date type="Actual">November 1, 2007</completion_date>
  <primary_completion_date type="Actual">November 1, 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability to administer, after priming with recombinant human hyaluronidase, at least one half of a 4-week dose (minimum of 200 mg/kg) of IgG in a single infusion site, via the subcutaneous route, with no more than mild local adverse drug reactions.</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Primary Immunodeficiency Diseases (PID)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tolerability of subcutaneous infusions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tolerability of subcutaneous infusions and pharmacokinetics</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant human hyaluronidase + immune globulin intravenous</intervention_name>
    <description>Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered</description>
    <arm_group_label>1</arm_group_label>
    <other_name>IGIV</other_name>
    <other_name>10% = Immune Globulin Intraveneous (Human)</other_name>
    <other_name>10%</other_name>
    <other_name>rHuPH20 = Recombinant Human Hyaluronidase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant human hyaluronidase + immune globulin intravenous</intervention_name>
    <description>IV infusion of IGIV, 10% to determine pharmacokinetics
Intervention as in Arm 1: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered</description>
    <arm_group_label>2</arm_group_label>
    <other_name>IGIV</other_name>
    <other_name>10% = Immune Globulin Intraveneous (Human)</other_name>
    <other_name>10%</other_name>
    <other_name>rHuPH20 = Recombinant Human Hyaluronidase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent from either the subject or the subject's legally acceptable
             representative

          -  Diagnosis of a PID disorder as defined by World Health Organization criteria1 for
             which the subject had been receiving a regimen of weekly or biweekly
             (every-other-week) subcutaneous IgG infusions or IGIV infusions every 21 to 28 days
             over a period of at least 8 weeks pre-study at an equivalent of a 4-week dose of 300
             to 800 mg/kg bodyweight

          -  Adults/adolescents aged 16 years and older)

          -  For female subjects of child-bearing age: negative urine pregnancy test result at
             study entry and agreement to employ adequate birth control measures for the duration
             of the study

        Exclusion Criteria:

          -  Subjects positive at enrollment for one or more of the following: HBsAg, PCR for HCV,
             PCR for HIV Type 1

          -  Subjects with levels of alanine aminotransferase (ALT) or aspartate aminotransferase
             (AST) &gt; 2.5 times the upper limit of normal for the testing laboratory

          -  Subjects with neutropenia (defined as an absolute neutrophil count [ANC] &lt;= 500/mm3).

          -  Subjects with serum creatinine levels greater than 1.5 times the upper limit of normal
             for age and gender

          -  Subjects with current history of malignancy

          -  Subjects with a history of thrombotic episodes (deep vein thrombosis, myocardial
             infarction, cerebrovascular accident)

          -  Subjects with abnormal protein loss (protein losing enteropathy, nephritic syndrome,
             severe lung disease)

          -  Subjects with anemia that in the opinion of the investigator precluded phlebotomy for
             laboratory studies

          -  Subjects who had been exposed to any blood or blood product other than an intravenous
             immunoglobulin (IGIV), SC immunoglobulin (SCIG), immune serum globulin (ISG)
             preparations, or albumin within the 6 months prior to study entry.

          -  Subjects with an ongoing history of hypersensitivity or persistent reactions
             (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IGIV,
             SCIG and/or ISG infusions

          -  Subjects with IgA deficiency and known anti IgA antibodies

          -  Subjects who had received antibiotic therapy for the treatment of infection within 7
             days prior to enrollment

          -  Subjects who had participated in another clinical study involving an investigational
             product or device within 28 days prior to study entry

          -  Subjects with inability or unwillingness to meet all the requirements of this study

          -  If female, pregnancy or lactation at time of study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>First Allergy and Clinical Research Center</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates of the Palm Beaches</name>
      <address>
        <city>North Palm Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrics Allergy/Immunology Association, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

